Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2026-04081 | Registry Identifier | CTRP (Clinical Trial Reporting Program) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Viewray Inc. | INDUSTRY |
Not provided
Not provided
Not provided
This clinical trial studies the side effects of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and to see how well it works in treating patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over 1-5 days. This type of radiation therapy helps spare normal tissue. During MR-guided SBRT, MR imaging is used to define and localize the area to be treated and provide more accurate delivery. This allows the treatment to be given over one day. MR-guided SBRT may be safe, tolerable, and/or effective in treating patients with metastatic solid tumors. Tumors in the central nervous system will not be treated on this study.
PRIMARY OBJECTIVE:
I. To evaluate the incidence of acute grade ≥ 3 adverse events that are possibly, probably, or definitely related to single-fraction adaptive MR-guided SBRT.
SECONDARY OBJECTIVES:
I. To estimate local control (LC), progression-free survival (PFS) and overall survival (OS).
II. To characterize late grade ≥ 3 toxicity rates per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.
III. To assess patient-reported health-related quality of life (HRQOL) using Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) at baseline, end of treatment, 3 months post-treatment, and 1 year post-treatment.
IV. To measure total in-room time, defined as the duration from patient entry to exit at the treatment console.
OUTLINE:
Patients undergo MR-guided SBRT over one treatment fraction on study. Patients also undergo magnetic resonance imaging (MRI) and computed tomography (CT) on study and CT or PET/CT throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment (MR-guided SBRT) | Experimental | Patients undergo MR-guided SBRT over one treatment fraction on study. Patients also undergo MRI and CT on study and CT or PET/CT throughout the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Computed Tomography | Procedure | Undergo CT and/or PET/CT |
|
| Measure | Description | Time Frame |
|---|---|---|
| Acute toxicity rate | Defined as the percentage of patients who experience acute grade ≥ 3 adverse events relating to single-fraction adaptive magnetic resonance-guided stereotactic body radiation therapy. Will be calculated, along with the corresponding 95% Clopper-Pearson exact confidence interval. Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 | Up to 3 months post-radiation therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Time to local failure (Local control) | As assessed by imaging and clinical evaluation, according to Response Evaluation Criteria in Solid Tumors version 1.1. Will be estimated via Kaplan-Meier (KM) analysis. The median survival along with 95% confidence interval will also be reported. | From end of study treatment to the presence of local or locoregional disease progression within the irradiated field, assessed up to 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Carol Felix | Contact | 310-825-9771 | cfelix@mednet.ucla.edu | |
| Christy Palodichuk | Contact | 1 310-794-2971 | cpalodichuk@mednet.ucla.edu |
| Name | Affiliation | Role |
|---|---|---|
| Ann Raldow, MD | UCLA / Jonsson Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Magnetic Resonance Imaging | Procedure | Undergo MRI |
|
|
| MRI-guided Stereotactic Body Radiation Therapy | Radiation | Undergo MR-guided SBRT |
|
|
| Positron Emission Tomography | Procedure | Undergo PET/CT |
|
|
| Questionnaire Administration | Other | Ancillary studies |
|
| Progression-free survival | Will be estimated via KM analysis. The median survival along with 95% confidence interval will also be reported. | From end of study treatment to the first documented evidence of disease progression or death from any cause, whichever occurs first, assessed up to 12 months |
| Overall survival | Will be estimated via KM analysis. The median survival along with 95% confidence interval will also be reported. | From end of study treatment to death from any cause, assessed up to 12 months |
| Incidence of late grade ≥ 3 toxicities | Assessed per CTCAE v5.0 for entire and sub-cohort, stratified by anatomic treatment site. Will be characterized via descriptive statistics. | From 3 months post-radiation therapy up to 12 months post-radiation therapy |
| PROMIS-29 patient-reported health-related quality-of-life (HRQOL) | Assessed using PROMIS-29 HRQOL questionnaires (Patient-Reported Outcomes Measurement Information System 29-item profile). Raw domain scores are converted to T-scores calibrated to the US general population, with a mean of 50 and standard deviation of 10. For symptom domains (anxiety, depression, fatigue, pain interference, sleep disturbance), higher scores indicate worse symptom burden. For functioning domains (physical function, social participation), higher scores indicate better functioning. Changes from baseline to 3 time points post-treatment will be analyzed. | Peritreatment/Periprocedural, 3 months post-treatment, and 12 months post-treatment |
| Total in-room time | The duration from patient entry to exit at the treatment console will be collected; summary statistics will be reported for entire cohort and sub-cohort of treated target number 1, 2 and 3, respectively. | From patient entry to exit at the treatment console, approximately one day |
| ID | Term |
|---|---|
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D009369 | Neoplasms |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D009682 | Magnetic Resonance Spectroscopy |
| ID | Term |
|---|---|
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
Not provided
Not provided